Please assess the completion status of the following clinical trial:

Trial Title: The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetic foot ulcer~* \< = 80 years old~* diabetic foot ulcer wegnar 2-4 stage~Exclusion Criteria:~* Wagner grade 0,1 and grade 5~* severe coronary, cerebral, renal vascular as well as severe liver diseases, malignant neoplasms~* bleeding individuals~* \> 80 years old~* heart failure (NYHA 3,4)~* cancer

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- continuous intra-femoral thrombolysis group (Type: EXPERIMENTAL): Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 \~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
- conventional therapy group (Type: ACTIVE_COMPARATOR): Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).